Bimekizumab efficacy in scalp, nail and palmoplantar psoriasis versus comparators and over 4 years - PubMed
3 days ago
- #bimekizumab
- #biologic-treatment
- #psoriasis
- Bimekizumab showed higher rates of complete clearance in scalp, nail, and palmoplantar psoriasis compared to adalimumab, ustekinumab, and secukinumab.
- At Week 24, bimekizumab achieved 77.7% scalp, 39.8% nail, and 78.7% palmoplantar clearance versus 58.1%, 24.5%, and 73.3% with adalimumab.
- By Week 52, bimekizumab maintained higher clearance rates (71.9% scalp, 54.0% nail, 85.2% palmoplantar) compared to ustekinumab (51.8%, 30.6%, 75.0%).
- At Week 48, bimekizumab outperformed secukinumab with 80.6% scalp, 69.5% nail, and 82.4% palmoplantar clearance versus 71.6%, 52.5%, and 76.8%.
- Long-term efficacy (4 years) showed sustained clearance: 79.5% scalp, 61.6% nail, and 88.7% palmoplantar psoriasis.
- Bimekizumab improved patient-reported quality of life more than comparators in high-impact areas.
- Clinical trials included BE SURE, BE VIVID, BE READY, BE RADIANT (48-56 weeks), and BE BRIGHT (144 weeks).